Trial Profile
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 15 Nov 2023 Status changed from active, no longer recruiting to completed.
- 28 Sep 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2025.
- 28 Sep 2023 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2025.